Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines

被引：1
|
作者：
Escudier, Bernard [1 ]
Joly, Florence [2 ]
Soria, Jean-Charles [3 ]
机构：
[1] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France
[2] Ctr Francois Baclesse, F-14076 Caen 05, France
[3] Inst Gustave Roussy, SITEP, F-94805 Villejuif, France
来源：
BULLETIN DU CANCER | 2011年 / 98卷
关键词：
renal cell carcinoma; immunotherapy; nephrectomy; anti-angiogenesis; mammalian target of rapamycin; guidelines; toxicities; CELL CARCINOMA; INTERFERON-ALPHA; DOUBLE-BLIND; TEMSIROLIMUS; SUNITINIB;
D O I：
10.1684/bdc.2011.1444
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Advanced renal cell carcinoma (RCC) is associated with a poor prognosis and is refractory to standard chemotherapy. Recent progress in the understanding of molecular biology and pathogenesis of renal cell cancer has been translated into the development of new therapeutic strategies. The management of metastatic RCC has been revolutionized with the development of targeted molecular therapies against VEGF-VEGFR and mTOR. Randomized phase III clinical trials demonstrated clinical benefit for patients with advanced RCC in overall survival and progression free survival. Guidelines for the management of side effects induced by these targeted therapies seem to be warranted. Delta
引用
收藏
页码：S3 / S6
页数：4
相关论文
共 50 条
  • [31] Targeted therapies for renal cell carcinoma
    Mary Lee H. Villanueva
    Ralph Hauke
    Targeted Oncology, 2007, 2 : 7 - 16
  • [32] Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors
    Cuyle, Pieter-Jan
    Prenen, Hans
    ANNALS OF GASTROENTEROLOGY, 2018, 31 (02): : 140 - 150
  • [33] Management of side effects of targeted therapies in renal cancer: sexual disorders
    Bessede, Thomas
    Joly, Florence
    Lebret, Thierry
    BULLETIN DU CANCER, 2011, 98 : S127 - S131
  • [34] Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
    Lainez, Nuria
    Garcia-Donas, Jesus
    Esteban, Emilio
    Puente, Javier
    Isabel Saez, M.
    Gallardo, Enrique
    Pinto-Marin, Alvaro
    Vazquez-Estevez, Sergio
    Leon, Luis
    Garcia-Carbonero, Icar
    Suarez-Rodriguez, Cristina
    Molins, Carmen
    Climent-Duran, Miguel A.
    Lazaro-Quintela, Martin
    Gonzalez del Alba, Aranzazu
    Jose Mendez-Vidal, Maria
    Chirivella, Isabel
    Afonso, Francisco J.
    Lopez-Brea, Marta
    Sala-Gonzalez, Nuria
    Domenech, Montserrat
    Basterretxea, Laura
    Santander-Lobera, Carmen
    Gil-Arnaiz, Irene
    Fernandez, Ovidio
    Caballero-Diaz, Cristina
    Mellado, Begona
    Marrupe, David
    Garcia-Sanchez, Jose
    Sanchez-Escribano, Ricardo
    Fernandez Parra, Eva
    Villa Guzman, Jose C.
    Martinez-Ortega, Esther
    Belen Gonzalez, Maria
    Moran, Marina
    Suarez-Paniagua, Beatriz
    Lecumberri, Maria J.
    Castellano, Daniel
    BMC CANCER, 2016, 16
  • [35] Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma
    Nerich, Virginie
    Hugues, Marion
    Paillard, Marie Justine
    Borowski, Laetitia
    Nai, Thierry
    Stein, Ulrich
    Hon, Thierry Nguyen Tan
    Montcuquet, Philippe
    Maurina, Tristan
    Mouillet, Guillaume
    Kleinclauss, Francois
    Pivot, Xavier
    Limat, Samuel
    Thiery-Vuillemin, Antoine
    ONCOTARGETS AND THERAPY, 2014, 7 : 365 - 374
  • [36] Targeted Therapies for Ovarian Cancer
    Grunewald, Tami
    Ledermann, Jonathan A.
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2017, 41 : 139 - 152
  • [37] Side-effects associated with targeted therapies in renal cell carcinoma
    Soulieres, Denis
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2013, 7 (03) : 254 - 257
  • [38] Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma
    Nouhaud, F. X.
    Rebibo, J. -D.
    Blanchard, F.
    Sabourin, J. -C.
    Di Fiore, F.
    Pfister, C.
    PROGRES EN UROLOGIE, 2014, 24 (09): : 563 - 571
  • [39] The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma
    Giri, Vinay K.
    Zaemes, Jacob
    EXPERT REVIEW OF ANTICANCER THERAPY, 2025, 25 (04) : 337 - 349
  • [40] Fatigue in Renal Cell Carcinoma: The Hidden Burden of Current Targeted Therapies
    Larkin, James M. G.
    Pyle, Lynda M.
    Gore, Martin E.
    ONCOLOGIST, 2010, 15 (11) : 1135 - 1146
12345